S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:NDRA

ENDRA Life Sciences - NDRA Price Target & Analyst Ratings

$0.18
0.00 (0.00%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.16
$0.34
52-Week Range
$0.16
$0.93
Volume
81,453 shs
Average Volume
1.05 million shs
Market Capitalization
$11.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.63

ENDRA Life Sciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$4.63
2,453.84% Upside
High Prediction$5.00
Average Prediction$4.63
Low Prediction$4.25
TypeCurrent
12/2/21 to 12/2/22
1 Month Ago
11/2/21 to 11/2/22
3 Months Ago
9/3/21 to 9/3/22
1 Year Ago
12/2/20 to 12/2/21
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$4.63$5.00$5.00N/A
Predicted Upside2,453.84% Upside1,136.09% Upside1,136.09% UpsideN/A
Get ENDRA Life Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.


NDRA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NDRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ENDRA Life Sciences Stock vs. The Competition

TypeENDRA Life SciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside2,453.84% Upside570.61% Upside11.38% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
234
62.57%
Underperform Votes
140
37.43%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/23/2022Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$4.25+2,499.24%
4/7/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$6.00 ➝ $5.00+1,136.07%
(Data available from 12/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NDRA Price Target - Frequently Asked Questions

What is ENDRA Life Sciences's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for ENDRA Life Sciences stock is Buy based on the current 1 buy rating for NDRA. The average twelve-month price prediction for ENDRA Life Sciences is $4.63 with a high price target of $5.00 and a low price target of $4.25. Learn more on NDRA's analyst rating history.

Do Wall Street analysts like ENDRA Life Sciences more than its competitors?

Analysts like ENDRA Life Sciences more than other Medical companies. The consensus rating score for ENDRA Life Sciences is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how NDRA compares to other companies.

Do MarketBeat users like ENDRA Life Sciences more than its competitors?

MarketBeat users like ENDRA Life Sciences less than other Medical companies. 62.57% of MarketBeat users gave ENDRA Life Sciences an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does ENDRA Life Sciences's stock price have much upside?

According to analysts, ENDRA Life Sciences's stock has a predicted upside of 1,326.74% based on their 12-month price targets.

What analysts cover ENDRA Life Sciences?

ENDRA Life Sciences has been rated by Ascendiant Capital Markets in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NDRA) was last updated on 12/2/2022 by MarketBeat.com Staff